New targeted drug shows promise for Hard-to-Treat lung cancer
Disease control
Not yet recruiting
This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. The goal is to see if setidegrasib can keep the cancer from growing longer and help peopl…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 17, 2026 00:50 UTC